Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to DO2005000230ApriorityCriticalpatent/DOP2005000230A/en
Publication of DOP2005000230ApublicationCriticalpatent/DOP2005000230A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invencion se refiere a agonistas del receptor a7 nicotinico de formula I como se describe en este documento y a un procedimiento para tratar trastomos del Sistema Nervioso Central (SNC) y otros trastornos en un mamifero, incluyendo un ser humano, administrando al mamifero un agonista del receptor a7 nicotinico de formula I. Tambien se refiere a composiciones farmaceuticas que contienen un vehiculo farmaceuticamente aceptable y un agonista del receptor a7 nicotinico penetrante del SNC de formula IThe present invention relates to nicotinic a7 receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human being, administering to the mammal an agonist. of the nicotinic a7 receptor of formula I. It also refers to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS penetrating nicotinic a7 receptor agonist of formula I
DO2005000230A2005-11-102005-11-10
AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS
DOP2005000230A
(en)
Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
Compounds derived from n - [(2-oxo-1,2-dihydro-3-pyridinyl) methyl] -1h-indole-4-carboxamide, ezh2 inhibitors; pharmaceutical composition that contains them; Useful in the treatment of cancer selected from the group consisting of brain (gliomas), glioblastomas, leukemias and lymphomas, and disorders mediated by the inhibition of ezh2.
Compounds derived from n-substituted azacyclylamines, histamine 3 receptor inhibitors; Preparation process; pharmaceutical composition comprising the compounds, and use for the treatment of cognitive disorders, schizophrenia and Alzheimer's disease among others.
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AN ANXIETY DISORDER INCLUDING EXO-7- (8-H-8-AZA-BICICLO (3,2,1) OCT-3-ILOXI) -CROMEN-2-ONA, USE AND EQUIPMENT